Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group studyLari Wenzel, Marion Piedmonte, Paul K. J. Han et al.|Gynecologic Oncology|2017Cited by 25
Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199)Joan L. Walker, Austin Miller, Mitchell H. Gail et al.|JNCI Cancer Spectrum|2019Cited by 18
Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG studyMartee L. Hensley, Helen Huang, Lari Wenzel et al.|Gynecologic Oncology|2019Cited by 14
Factors Associated With Deciding Between Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening Among High-Risk Women Enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group StudyLari Wenzel, Marion Piedmonte, Paul K. J. Han et al.|Obstetrical & Gynecological Survey|2017Cited by 1
Abstract PO018: PAX8 represents a potential novel therapeutic target in copy number high uterine serous carcinomaSusan Read, Bing Zhang, Matthew L. Anderson et al.|Clinical Cancer Research|2021Cited by 0